Author

P. B. Staber

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Approach:statistical model· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:chromatin & epigenetic regulation· 2 Research Focus:cell signaling & trafficking· 1 Assay:ChIP-seq· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. Di Ruscio· 2 shared A. K. Ebralidze· 2 shared A. Pichler· 2 shared B. Q. Trinh· 2 shared D. G. Tenen· 2 shared E. van der Kouwe· 2 shared G. Heller· 2 shared A. Boersma· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Di Ruscio

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

STAT5 Gain-of-Function Variants Promote Precursor T-Cell Receptor Activation to Drive T-Cell Acute Lymphoblastic Leukemia

T. Suske, H. Sorger, F. Ruge, N. Prutsch, M. W. Zimmerman, T. Eder, B. Maurer, C. Wagner, S. Schoenefeldt, K. Spirk, A. Pichler, T. Pemovska, C. Schweicker, D. Poeloeske, D. Jungherz, , R. Moriggl

This study identifies STAT5 gain-of-function mutations as drivers of T-ALL by promoting pre-TCR signaling and shows therapeutic targeting potential with STAT3/5 or ZAP70 inhibitors.

bioRxiv · Dec 21, 2022 · PreprintCancer Biology

Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter

E. van der Kouwe, G. Heller, A. Czibere, L. H. Castilla, R. Delwel, A. Di Ruscio, A. K. Ebralidze, M. Forte, L. Kazianka, C. Kornauth, T. Le, K. Lind, I. A. Monteiro Barbosa, A. Pichler, J. A. Pulikkan, , P. B. Staber

The paper shows that CBF fusions in AML activate the PU.1 antisense promoter, reducing sense PU.1 transcription and blocking myeloid differentiation, similar to T-cell differentiation.

Blood · Oct 14, 2021Peer-reviewedCancer Biology

DNMT3A harboring leukemia-associated mutations directs sensitivity to DNA damage at replication forks

K. Venugopal, P. Nowialis, Y. Feng, D. E. Shabashvili, C. M. Berntsen, K. I. Krajcik, C. Taragjini, Z. Zaroogian, H. L. Casellas-Roman, L. M. Posada, C. Gunaratne, J. Li, D. Dupere-Richer, R. L. Bennett, S. Pondugula, , O. A. Guryanova

This study shows that DNMT3A mutations impair replication fork recovery, leading to DNA damage and sensitivity to nucleoside analogs like cytarabine.

bioRxiv · May 28, 2021Cancer Biology

Myeloid lncRNA LOUP Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML

B. Q. Trinh, S. Ummarino, A. K. Ebralidze, E. van der Kouwe, M. A. Bassal, T. M. Nguyen, R. Coffey, D. E. Tenen, E. Fabiani, C. Gurnari, C.-S. Wu, V. E. Angarica, Y. Zhang, L. Ying, H. Yang, , D. G. Tenen

The paper identifies the long noncoding RNA LOUP as a mediator of RUNX1 and RUNX1-ETO effects in t(8;21) AML, showing it promotes myeloid differentiation and inhibits cell growth by regulating PU.1 expression.

bioRxiv · Jul 24, 2020Cancer Biology